Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00219180 · ClinicalTrials.gov registry record · Phase 3
Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,797
- Enrollment target
NCT00219180 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 1,797 participants.
The verdict
NCT00219180, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,797 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of aliskiren alone and in combination with valsartan given to patients with essential hypertension
Interventions
- DRUG aliskiren
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,797 participants |
| Start Date | 2005-06 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00219180
The ClinicalTrials.gov registry entry for NCT00219180 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,797 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which aliskiren is the first listed.
NCT00219180 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00219180 about?
NCT00219180 is a clinical study titled "Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure". To evaluate the efficacy and safety of aliskiren alone and in combination with valsartan given to patients with essential hypertension
What is the current status of trial NCT00219180?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,797 participants. The study started on 2005-06. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00219180?
The interventions under investigation include: aliskiren (DRUG).
Who is sponsoring clinical trial NCT00219180?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.